New drug targets scarring in Crohn's – first look in humans

This early-phase study tests an experimental drug called PALI-2108 in a small group of people with fibrostenotic Crohn's disease, a condition where the gut becomes scarred and narrow. The main goal is to see how the drug affects inflammation and scarring at the molecular level by analyzing tissue and blood samples before and after 14 days of treatment. Safety and how the drug moves through the body are also checked. This is not a treatment study—it is designed to learn how the drug works in the body.